Selinexor in combination with ruxolitinib achieved a statistically significant improvement in spleen volume reduction for patients with MF, according to a press release. Rare Disease Advisor, a ...

Lower rates of chronic and acute GVHD, infections, and nonrelapse mortality indicate a substantially reduced toxicity burden. In patients with myelodysplastic syndrome (MDS) and acute leukemias ...

IgG MGUS was associated with less frequent acute onset (6% vs 33%) and more frequent sensory deficits at onset (94% vs 67%). Immunoglobulin G (IgG) monoclonal gammopathy of undetermined significance ...

(Getty Images) The analysis included 486 HELIOS-B participants with KCCQ assessments at both baseline and 30 months. The greatest differences in score change occurred in questionnaire items gauging ...

In a phase 3 trial, participants taking venglustat demonstrated statistically significant improvement in neurological symptoms compared with those receiving ERT. Sanofi announced that the US Food and ...

Researchers are beginning to investigate the role antibody-microbiota dynamics play in myasthenia gravis (MG). The gut microbiome is a diverse community that evolved alongside the immune system, ...

Physicians should actively involve caregivers in treatment decisions and provide clear expectations regarding treatment efficacy and adverse effects. An international panel of experts provided ...

The combination of not using glucosamine and high genetic predisposition markedly increased the likelihood of developing IPF. Regular glucosamine use is associated with a decreased risk of developing ...

Outcomes remained poor overall, underscoring the need for clinical trials and novel therapies in this setting. Nonetheless, prognosis remained limited in this heavily pretreated population. The ...

Overall survival was similar between groups, likely due to effective BTK inhibitor salvage after lenalidomide relapse. Bruton tyrosine kinase inhibitor (BTKi) maintenance therapy was associated with ...

The discontinuation was not driven by safety concerns, as emugrobart was well tolerated, with no serious adverse events resulting in study withdrawal. Roche and Genentech have announced that they are ...